Hidradenitis Suppurativa

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

These data expand upon existing literature on pediatric HS and racial differences among patients based on management, presentation, and severity.

These data highlight a variety of comorbidities linked to dermatologic diseases in children with obesity, including common comorbidities such as asthma.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.

This literature review explored the topic of hidradenitis suppurativa management during pregnancy and lactation, highlighting data available on this topic.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

These findings highlight the value in understanding and recognizing gender differences in patient experiences with hidradenitis suppurativa and their impact on life quality.

Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.

In this analysis, a retrospective and multi-center study was conducted to determine any predictors of biological therapy intensification in individuals with HS.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials.

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa.

In this 5-part, expert-led series, a pair of dermatologists break down how the FDA approval of bimekizumab impacts the treatment landscape of HS.

This meta-analysis showed that both secondary closure techniques substantially reduce the risk of hidradenitis suppurativa recurrence compared to primary direct closure.

UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.

These data on patients with hidradenitis suppurativa point to several factors as being associated with diagnostic wandering.

This analysis highlighted links between depression, stigmatization, anxiety, and health- and disease-related variables among individuals with HS in Europe.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.